Osteonecrosis of the talus is a rare condition affecting fairly young people; MRI is the diagnostic method of choice, and core decompression with intraosseous stem cell injection provides a feasible treatment option for the early-stage talar osteonecrosis.
radiographic sclerosis develops in the infarcted bone, corresponding low signal on both T1-and T2-weighted images can be detected. The reparative zone between necrotic tissue and viable granulation tissue represents the "double-line sign," a low-signal rim in which the inner aspect becomes high signal on T2-weighted images [4, 8] . Many classification systems for osteonecrosis exist, and the Association Research Circulation Osseous (ARCO) system was selected for this case report [9] . To the orthopedic surgeon, the osteonecrosis of the talus represents a dilemma; while several treatment options exist, the outcomes have remained suboptimal [10] . Moreover, while a plethora of treatment choices is available -including restricted weight-bearing, bracing, bone grafting, core decompression, talectomy, and arthrodesis -no consensus for the ideal treatment strategy for the talar osteonecrosis exists [10] . Here, we report a successful treatment of early osteonecrosis of the talus (ARCO Stage I) using core decompression combined with intraosseous stem cell and platelet-rich plasma (PRP) injection. This technique has been introduced by Hernigou and Beaujean mainly to treat osteonecrosis of the femoral head [11] . To the best of our knowledge, no prior literature exists where this modified technique had been used to treat talar osteonecrosis.
Case report :
A 45-year-old man (treated from 11/2014 to 06/2016) with hypertension and hypothyroidism medications had twisted his right ankle while walking his dog. Primarily, he presented edema around the lateral malleolus, and no fracture was detected on radiographs (figure not shown); thus, conservative treatment with ankle brace was initiated. The pain in the ankle persisted for 3 months, and subsequent follow-up radiographs, and eventually MRI of the ankle was performed. The radiographs were normal (Fig. 1a) , but the MRI revealed ARCO Stage I osteonecrosis of the talus with increased signal on T2-weighted fat-saturated images and decreased signal on T1-weighted images; an additional minor crescent sign was also present ( Fig. 2a and b) . Due to the persisting pain and poor strain tolerance, core decompression with stem cell and PRP injection was performed using GPS® III (Gravitational Platelet Separation System; Zimmer-Biomet, Warsaw, Indiana, USA) and BioCUE BMA (Bone Marrow A spirate [BMA] Concentration System; Zimmer-Biomet, Warsaw, Indiana, USA) systems. First, 30 ml of venous blood (including 3 ml of anticoagulant) was collected from the patient and centrifuged for 15 min. Accordingly, 3 ml of PRP was recovered from the centrifuged sample. In operating room under general anesthesia, autologous aspiration of bone marrow-derived stem cells from the right anterior iliac crest was carried out by an orthopedic surgeon. In total, 60 ml of BMA was collected and subsequently centrifuged for 15 min producing 6 ml of concentrated BMA. Finally, the PRP and BMA were mixed producing a total of 9 ml of the injectate. A stab incision on the anteroinferior edge of the medial malleolus was performed, and on fluoroscopic control, a guidance spike was directed into the talus to the region of the osteonecrosis. A 2.7 mm cannulated drill was used to provide core decompression. Routine Mortise projections of the right ankle. After persisting ankle pain, on 3-month followup, the radiographs were interpreted as normal with no signs of osteonecrosis (a). On 4-week post-procedure clinical follow-up, the ankle was painless, but due to restricted weight-bearing, the mineral density of the ankle had decreased as seen on radiographs (b). On the last follow-up (15 months after the procedure), the ankle was symptomless and radiographs were interpreted as normal (c). The procedure using fluoroscopic guidance, core decompression of the talar dome was performed using a guidance spike (arrowhead) and a 2.7 mm drill (arrow) (a). In addition to standard procedure, autologic mesenchymal stem cells combined with platelet-rich plasma were injected into the osteonecrotic region in the talus (b).
histopathological specimens were not produced due to typical findings of osteonecrosis on MRI. Next, the PRP-BMA concoction was injected into the osteonecrotic region under fluoroscopic control using a 3 mm aspiration needle (Fig. 3) . The incision wound was closed and full weight-bearing was restricted for 4 weeks with free mobilization of the ankle. On 4-week clinical follow-up, the patient presented no pain in the right ankle. Radiographs were normal except for the low mineral density of the bones in general (Fig. 1b) . On the 3-month follow-up, the patient had fully resumed to his daily activities and his ankle was symptomless. The MRI revealed virtually complete resolution of the talar osteonecrotic changes (Fig. 2c  and d) . On the subsequent 15-month follow-up, the patient presented no symptoms and the MRI scan ( Fig. 2e and f) as well as the radiographs (Fig. 1c) were normal.
Discussion:
The talus is uncommonly affected by osteonecrosis with an unknown incidence. Core decompression has been suggested as an alternative for the treatment of non-traumatic osteonecrosis of the talus without collapse by decreasing intraosseous pressure and promoting revascularization [12] . A study by Mont et al. concluded that core decompression is a feasible method of treatment for symptomatic osteonecrosis of the talus before collapse; at 7-year follow-up, 14 of the 17 ankles treated by core decompression had excellent or good result [13] . Another study also supported core decompression in symptomatic atraumatic talar osteonecrosis before collapse by reporting fair to excellent results in 29 of 32 patients [14] . A more recent study by Marulanda et al. depicted 44 ankles treated with core decompression, out of which 40 (91%) displayed good to excellent clinical outcomes in 4-year followup [15] . Overall, 28% of patients experience radiologic progression of the osteonecrosis [13, 14, 15] . Moreover, Issa et al. reported in their study that out of 85 ankles treated by core decompression only 17% demonstrated disease progression [16] . According to a fairly recent systematic review by Gross et al., the recapitulation of these results is that core decompression is an appropriate procedure in patients with early and late stage osteonecrosis secondary to atraumatic etiologies. However, further research is warranted to evaluate the role of core decompression in the treatment of traumatic talar osteonecrosis [10] . In addition to normal core decompression, Hernigou and Beaujean have introduced a method combining core decompression with intraosseous stem cell and PRP injection in the treatment of osteonecrosis of the femoral head [11] . Furthermore, two recent meta-analyses by Papakostidis et al. and Piuzzi et al. showed that on early-stage osteonecrosis of the femoral head the combined approach improves patients' prognosis when compared to plain core decompression [17, 18] . Here, we have described a case with successful treatment of ARCO Stage I talar osteonecrosis using this combined technique. Initially, the patient presented a minor ankle sprain with persisting pain. The radiographs showed no diagnostic findings, and after definitive MRI diagnosis for early talar osteonecrosis, core decompression with stem cell and PRP injection was performed. Due to the typical MRI appearance of osteonecrosis, histopathological samples were not routinely collected. The differential diagnosis on this case might include insufficiency fracture of the talus and transient bone marrow edema, but since persisting pain and the crescent sign seen on MRI, ARCO Stage I osteonecrosis represents the most plausible diagnosis. On follow-up visits, the patient was symptomless and MRI findings of the osteonecrosis were seen to resolve.
